NIKKEI 225
28,641.95 -162.90 (-0.57%) HANG SENG
26,126.93 +109.43 (+0.42%) CRUDE OIL
84.36 +0.60 (+0.72%) GOLD FUTURES
1,796.00 -0.30 (-0.02%) DOW
35,677.02 +73.92 (+0.21%) BTC-GBP
45,022.22 +500.25 (+1.12%)
MorphoSys AG (MPSYF)
| Previous close | 43.59 |
| Open | 44.19 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 43.59 - 43.59 |
| 52-week range | 43.59 - 119.38 |
| Volume | 500 |
| Avg. volume | 29 |
| Market cap | 1.535B |
| Beta (5Y monthly) | 0.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.65 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous/Study20.10.2021 / 22:01 The issuer is solely responsible for the content of this announcement.First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A NephropathyMorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN). IgAN, also known as Berger's disease, is a ch
- Zacks
MorphoSys AG Unsponsored ADR (MOR) Upgraded to Strong Buy: Here's What You Should Know
MorphoSys AG Unsponsored ADR (MOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- EQS Group
MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous11.10.2021 / 08:47 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, October 11, 2021MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) received Breakthrough Therapy Designation by the U.S. Food and Drug Admin
